

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 August 2022 (18.08.2022)



(10) International Publication Number
WO 2022/173853 A1

(51) International Patent Classification:

A61K 31/435 (2006.01) *A61K 31/41* (2006.01)
A61K 9/00 (2006.01) *A61K 31/4166* (2006.01)
A61K 31/165 (2006.01) *A61P 25/00* (2006.01)
A61K 31/19 (2006.01) *A61P 25/08* (2006.01)
A61K 31/4015 (2006.01)

(21) International Application Number:

PCT/US2022/015851

(22) International Filing Date:

09 February 2022 (09.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/147,736 09 February 2021 (09.02.2021) US

(71) Applicant: **XENON PHARMACEUTICALS INC.**
[CA/CA]; 200-3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA).

(71) Applicant (for MW only): **RABINOWITZ, Stephen S.**
[US/US]; Dechert LLP, Three Bryant Park, 1095 Avenue of the Americas, New York, New York 10036-6797 (US).

(72) Inventor: **JOHNSON, JR, James Philip**; 200-3650 Gilmore Way, Burnaby, British Columbia V5G 4W8 (CA).

(74) Agent: **RABINOWITZ, Stephen S.** et al.; WOLF, GREENFIELD & SACKS, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS




FIG. 1

(57) Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human in need thereof, wherein the methods and uses comprise conjointly administering *N*-[4-(6-fluoro-3,4-dihydro-1*H*-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) and an antiseizure medication (ASM) to the human in amounts that are therapeutically effective when conjointly administered. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*